drugset / Trial / NCT01674192

Prucalopride Subjects With Renal Impairment

NCT01674192

Phase 1 Completed 34 enrolled Movetis
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics of a single 2 mg oral dose of prucalopride in subjects with various degrees of renal impairment compared with normal renal function and to monitor the safety profile of prucalopride in subjects with renal impairment. Hypothesis: Prucalopride might accumulate and exhibit a different pharmacokinetic profile in renally impaired subjects compared with the normal population.

Timeline

Start
1997-07
Primary completion
1999-08
Completion
1999-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Prucalopride Small molecule 2 mg Oral

Indications